Cargando…

Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis

We aimed to investigate the prognostic value of chromogranin A (CgA) in castration-resistant prostate cancer (CRPC). We conducted a systematic literature search of PubMed, Web of Science, and EMBASE for citations published prior to September 2017 that described CgA and CRPC and performed a standard...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hong, Peng, Guo, Run-Qi, Song, Gang, Yang, Kai-Wei, Zhang, Lei, Li, Xue-Song, Zhang, Kai, Zhou, Li-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219310/ https://www.ncbi.nlm.nih.gov/pubmed/30084431 http://dx.doi.org/10.4103/aja.aja_57_18

Ejemplares similares

Chromogranin A: a useful biomarker in castration-resistant prostate cancer
por: Ploussard, Guillaume, et al.
Publicado: (2022)

Serum Chromogranin-A based Prognosis In Metastatic Castration Resistant Prostate Cancer
por: Giridhar, Karthik V., et al.
Publicado: (2018)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
por: Li, Qi, et al.
Publicado: (2019)

Prognostic value of the bone scan index in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
por: Song, Hualin, et al.
Publicado: (2020)

A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer
por: Qi, Ping, et al.
Publicado: (2015)

Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer
por: Huang, Zhuo, et al.
Publicado: (2023)

PSMA theragnostics for metastatic castration resistant prostate cancer
por: Song, Hong, et al.
Publicado: (2022)

Prognostic impact of chromogranin A in patients with acute heart failure
por: Kim, Hong Nyun, et al.
Publicado: (2021)

Chromogranin A is a predictor of prognosis in patients with prostate cancer: a systematic review and meta-analysis
por: Guo, Zhenlang, et al.
Publicado: (2019)

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
por: Wang, Li, et al.
Publicado: (2015)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
por: Yi, Renliang, et al.
Publicado: (2016)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Meta-analysis of efficacy and safety of custirsen in patients with metastatic castration-resistant prostate cancer
por: Zhang, Xuebao, et al.
Publicado: (2019)

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer
por: Tsao, Che-Kai, et al.
Publicado: (2011)

Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer
por: Yun, Seok Joong, et al.
Publicado: (2017)

Editorial: Response and Resistance in Castration-Resistant Prostate Cancer
por: de Leeuw, Renée, et al.
Publicado: (2020)

Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Miura, Noriyoshi, et al.
Publicado: (2020)

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2018)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients
por: Lin, Ting-Ting, et al.
Publicado: (2019)

PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China
por: Wu, Kai-Jie, et al.
Publicado: (2018)

Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer
por: Park, Jeong Min, et al.
Publicado: (2012)

Prognostic value of circulating chromogranin A levels in acute coronary syndromes
por: Jansson, Anna M., et al.
Publicado: (2009)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
por: Tian, Shengri, et al.
Publicado: (2020)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Molecular and cellular mechanisms of castration resistant prostate cancer
por: Huang, Yiqiao, et al.
Publicado: (2018)

Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis
por: Qin, Zhiqiang, et al.
Publicado: (2016)

Low Efficacy of Chromogranin A Elimination by Therapeutic Plasma Exchange for Treatment of Chromogranin A Tubulopathy
por: Hakroush, Samy, et al.
Publicado: (2021)

Identification of genes associated with castration-resistant prostate cancer by gene expression profile analysis
por: Huang, Chui Guo, et al.
Publicado: (2017)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro
por: Xu, Yalan, et al.
Publicado: (2022)

20(S)-Protopanaxadiol Inhibition of Progression and Growth of Castration-Resistant Prostate Cancer
por: Cao, Bo, et al.
Publicado: (2014)

Chromogranin A regulates neuroblastoma proliferation and phenotype
por: Zhang, Dongyun, et al.
Publicado: (2019)

Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wang, Jiaxin, et al.
Publicado: (2020)

Chromogranin A, a significant prognostic factor in small cell lung cancer
por: Drivsholm, L, et al.
Publicado: (1999)

Prognostic value of circulating chromogranin A levels in acute coronary syndrome: reply
por: Røsjø, Helge, et al.
Publicado: (2010)

Prognostic value of chromogranin A in patients with GET/NEN in the pancreas and the small intestine
por: Fuksiewicz, Małgorzata, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1dsjlq6jrprb693b9s2sj30taa